

ASX Announcement

4 June 2026

OPAL RWA-Tokenised Product Sales Eclipse \$1m in Just 7 Weeks with >400 Distribution Partners Now Onboard

4 June 2026. Hong Kong, China. **Xenitra Limited (ASX: XEN)** or (the "Company") is pleased to advise shareholders that sales of products through the OPAL Real World Asset ("RWA") tokenised sales ecosystem have surpassed \$1,100,000, with more than >400 distribution partners now onboarded in 7 weeks. The result shows an acceleration in sales and network building velocity after \$500k in tokenised products were sold and >100 distribution partners joined the ecosystem in the first month.

Highlights

- Product Sales in the OPAL tokenised channel have scaled rapidly from launch to over \$1,100,000 in just 7 weeks after surpassing \$500k in sales in the first month, demonstrating strong acceleration.
- The network has expanded from zero to over 400+ distribution partners in this time demonstrating a powerful sales network is building, which can be leveraged for future product launches.
- OPAL Token utility is directly tied to real product purchases, creating a sustainable, self-reinforcing ecosystem that is now proven to deliver rapid product uptake in the China market for brand partners.
- Product sales in the channel have accelerated throughout the quarter, validating the high level of consumer demand and establishing a growing and active distributor base across Greater China.

Non-Executive Chairman, Dr Anthony Noble, commented: *"Exceeding \$1,100,000 in sales with over 400 distribution partners now onboarded; in just over half of one financial quarter, is a tremendous validation of the OPAL-Tokenised sales ecosystem. This result also highlights the level of consumer demand that we are seeing for premium Australian brands. We are building something truly unique and fully differentiated in the market: a blockchain-powered sales network that is anchored by real product purchases and real sales revenue. We have also now brought our second brand partner into the ecosystem - Biomiq Skincare. This sales model is now proven and the network is growing fast – but this is just the beginning."*

-Ends-

This announcement has been approved for release By The Board of Xenitra Limited.



Scaling brands in Asia with
*authentic products and
loyal customers*

ASX: XEN

 Xenitra.com

ASX Announcement

4 June 2026

Investor Relations Contact:

Blackwater Advisors

Harry Spillane | **Investor Relations**

harry@blackwateradvisors.com.au

+61 447 757 550

About Xenitra Limited

Xenitra specialises in fast-moving consumer goods (FMCG), nutraceuticals, over-the-counter (OTC) medicine and personal care products that are sold through a channel optimised sales ecosystem including blockchain tokenised distribution channels spanning Business-to-Business (B2B) trading, retail distribution and all major ecommerce platforms in China. Xenitra is an established brand acceleration partner for western brands entering the Asian markets. Through our proprietary platform, we have a proven track record of delivering exceptional market integration, providing marketing insights and delivering sales velocity.

Forward Looking Statements

This announcement may contain forward-looking statements, including statements regarding: plans, strategies and objectives of management; anticipated revenue, products, and stores; operating costs; Chinese tourism; Governmental policies and preferences (both Australian and Chinese). Forward-looking statements can be identified by the use of terminology such as 'intend', 'aim', 'project', 'anticipate', 'estimate', 'plan', 'believe', 'expect', 'may', 'should', 'will', 'continue', 'annualised' or similar words. These statements discuss future expectations concerning the results of operations or financial condition, or provide other forward-looking statements. These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are cautioned not to put undue reliance on forward-looking statements. Except as required by applicable regulations or by law, the Group does not undertake any obligation to publicly update or review any forward-looking statements, whether as a result of new information or future events. Past performance cannot be relied on as a guide to future performance.

